Documents

A list of downloadable documents created during development.

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form ^{PDF 50.7 KB} 19 March 2013

Diabetes (type 2) - dapagliflozin: appraisal consultation

Diabetes (type 2) - dapagliflozin: appraisal consultation
Diabetes (type 2) - dapagliflozin: appraisal consultation document information
Diabetes (type 2) - dapagliflozin: evaluation report
Diabetes (type 2) - dapagliflozin: pre-briefing meeting ^{PDF 749.04 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Evidence Review Group report
Diabetes (type 2) - dapagliflozin: Evidence Review Group report ^{PDF 1.35 MB} 01 February 2013
Diabetes (type 2) - dapagliflozin: changes to the ERG report ^{PDF 280.91 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Decision Support Unit report ^{PDF 875.08 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Evidence Review Group report - factual accuracy check ^{PDF 117.32 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: ERG BMI analyses ^{PDF 105.25 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: manufacturer submission
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca ^{PDF 5.56 MB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Bristol Myers-Squibb and AstraZeneca addendum ^{PDF 740.56 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: clarification
Diabetes (type 2) - dapagliflozin: NICE clarification letter ^{PDF 101.62 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Manufacturer response to the NICE clarification letter ^{PDF 958.51 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: ERG's additional clarification questions and manufacturer responses ^{PDF 440.1 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: patient group, professional group and NHS organisation submission statements
Diabetes (type 2) - dapagliflozin: Royal College of Nursing ^{PDF 10.76 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Royal College of Pathologists ^{PDF 50.68 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: NHS Middlesbrough ^{PDF 56.74 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: expert written personal statements
Diabetes (type 2) - dapagliflozin: Kilpatrick Appendix D - clinical specialist statement ^{PDF 33.47 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Kuti Appendix K - patient/carer expert statement ^{PDF 213.87 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Linton - Appendix K NHS-Commissioning expert statement declaration ^{PDF 29.19 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Moulton - Appendix K - Patient/carer expert statement ^{PDF 105.82 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Ononeze - Appendix K NHS-Commissioning expert statement declaration ^{PDF 8.57 KB} 01 February 2013
Diabetes (type 2) - dapagliflozin: Winocour - Appendix D clinical specialist statement ^{PDF 81.02 KB} 01 February 2013

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping ^{PDF 32.29 KB} 31 May 2012

Diabetes (type 2) - dapagliflozin: appendix B - final scope

Diabetes (type 2) - dapagliflozin: appendix B - final scope ^{PDF 67.02 KB} 25 May 2012

Diabetes (type 2) - dapagliflozin: appendix C - final matrix

Diabetes (type 2) - dapagliflozin: appendix C - final matrix ^{PDF 32.86 KB} 25 May 2012

Diabetes (type 2) - dapagliflozin: appendix D - comments table

Diabetes (type 2) - dapagliflozin: appendix D - comments table ^{PDF 226.78 KB} 25 May 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012 ^{PDF 77.55 KB} 24 April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012 ^{PDF 38.58 KB} 23 April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011 ^{PDF 67.99 KB} 24 April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011 ^{PDF 36.46 KB} 24 April 2012

Dapagliflozin in combination therapy for treating type 2 diabetes

Review proposal consultation

Diabetes (type 2) ? dapagliflozin: equality impact assessment - guidance review

Diabetes (type 2) - dapagliflozin: final appraisal determination

Diabetes (type 2) - dapagliflozin: Decision Support Unit project specification form

Diabetes (type 2) - dapagliflozin: appraisal consultation

Diabetes (type 2) - dapagliflozin: equality impact assessment - scoping

Diabetes (type 2) - dapagliflozin: appendix B - final scope

Diabetes (type 2) - dapagliflozin: appendix C - final matrix

Diabetes (type 2) - dapagliflozin: appendix D - comments table

Diabetes (type 2) - dapagliflozin [ID427]: appendix A - draft scope for consultation - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - provisional matrix - April 2012

Diabetes (type 2) - dapagliflozin [ID427]: appendix B - draft scope for consultation (pre-referral) - May 2011

Diabetes (type 2) - dapagliflozin [ID427]: appendix C - provisional matrix (pre-referral) - May 2011